HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer

Oral paclitaxel yields better outcomes than IV paclitaxel in metastatic breast cancer

Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer

The challenges of treating breast cancer in Brazil

The importance of central pathology pCR review in an international multicenter neoadjuvant study in HER2 positive early BC

SABCS 2019 highlights

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer

Imaging for women who are high risk of breast cancer

Adding S-1 to post-operative endocrine therapy in patients with hormone receptor-positive HER2-negative breast cancer

Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer

KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs placebo for early TNBC

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer

Implementation of genetic testing in breast cancer patients

Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC

Breast cancer screening and treatment in Brazil

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer

Long-term influence of oestrogen plus progestin vs oestrogen alone on breast cancer incidence in post-menopausal women

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer

Circulating tumour DNA used to predict disease recurrence for early triple-negative breast cancer

Oral paclitaxel with encequidar in metastatic breast cancer

Pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembrolizumab in TNBC patients

Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic complete response rates for TNBC patients

Breast cancer prevention in high-risk post-menopausal women

Accelerated partial breast irradiation versus whole breast irradiation in patients with early breast cancer

Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer

Preventative effects of anastrozole in post-menopausal women who are at high-risk for developing breast cancer

How effective is accelerated partial breast irradiation in patients with early breast cancer?

Predicting disease recurrence in patients with early triple-negative breast cancer using circulating tumour DNA

The emerging role of immunotherapy for the treatment of early and advanced breast cancer

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer

Breast cancer incidence in post-menopausal women: Long-term influence of oestrogen plus progestin versus oestrogen alone

Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients?

Addition of S-1 to post-operative endocrine therapy for patients with hormone receptor-positive HER2-negative breast cancer

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer